# PROACC-1 (NCT05546476)

> Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05546476
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Non-small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer; Loss of Appetite; Fatigue; Cachexia
- Interventions: ponsegromab; Placebo for ponsegromab
- Enrollment: 187
- Primary outcome: Part A: Change From Baseline in Body Weight at Week 12

## Indexed commentary on PROACC-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=proacc-1-nct05546476